There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.

Tactics and Strategies for Designing an Ideal Lentiviral Vector Platform

A slew of late-stage clinical trials is expected to push new regenerative medicines onto the market in the next few years.

Robust Development Fuels Drive to Finish Line

In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.

Technology for In Vivo CAR T-cell Therapy Advances

Topic

Claudia Berdugo-Davis, PhD, is director of Process Development, Catalent Biologics.

Danielle Wittenwyler, PhD, is manager, Manufacturing Science & Technology, Catalent Biologics.

Articles

Understanding processes in the development and manufacture of biological drug substances is crucial to successfully navigating the clinical phases towards commercial launch, all within ever‑tightening time constraints, and regulatory frameworks.

Streamlining and Standardizing Process Characterization

Webcasts

Webinar Date/Time: Wed, Jun 14, 2023 10:00 AM EDT


Best Practices for Mass Spectrometry-Based Multi-Attribute Method (MAM) for Therapeutic Proteins: USP General Chapter <1060>

Feliza Mirasol is the science editor for 

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.


Ramping Up Nucleic Acid Therapy Development

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Batch-to-batch variability and impurities present critical challenges.

Cryo/Lyoprotectants Quality Challenges

Brian Huber is vice-president of Therapeutic Areas, Drug Development, and Consulting at ICON.

Tamie Joeckel is global business lead of the Cell and Gene Therapy Group at ICON.

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

Challenges of Expanding CAR-T Cell Therapy into Solid Tumors

Webinar Dates/Times:
Thursday, June 29, 2023 at 17:00 CEST | 11:00 EDT | 08:00 PDT

Optimizing and Automating Peptide Mapping Workflow by Reducing Missed Cleavages and Improving to High-Throughput Chromatography

Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics. 

Aspect Biosystems, Novo Nordisk Partner to Develop Bioprinted Tissue Therapeutics 

Grant Playter is the Assistant Editor for 

BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services. 

BioChain Institute Extends Spatial Multiomics Services

The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.

EHA Data Leak Shows Positive J&J Cancer Treatment Findings

Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics